Domo arigato
Germany’s Kinaxo signs cancer research agreement with Japan’s Daiichi Sankyo
Register for free to listen to this article
Listen with Speechify
0:00
5:00
MARTINSRIED, Germany—Kinaxo Biotechnologies GmbH and Daiichi Sankyo Co. Ltd. recently reached an agreement for a long-term partnership in cancer research.
Under terms of the agreement, Daiichi Sankyo will employ Kinaxo's technology platform to support the development of Daiichi Sankyo's targeted cancer drugs. This will involve Kinaxo applying its proprietary chemical proteomics technologies, Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology, PhosphoScout, within various research programs pursued at Daiichi Sankyo.
Financial details of the agreement were not disclosed.
In a statement, Daiichi Sankyo said this is the first time the two companies have worked together, and Kinaxo's prominent proteomics technologies made it an attractive partner for Daiichi Sankyo. Daiichi Sankyo added that Kinaxo's technologies can provide the potential of clinical applications for personalized medicine.
The goals of the collaboration are to target kinase validation and mode of action analysis.
"To promote innovation in cancer therapy, we need to better understand how targeted drugs interfere with de-regulated signaling in human malignancies," says Axel Ullrich, director at the Max Planck Institute for Biochemistry in Martinsried and a Kinaxo board member. "To this end, Kinaxo has established a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment. I am convinced that these innovative technologies will significantly contribute to the development of tomorrow's cancer therapeutics."
Cellular Target Profiling and KinAffinity use a combination of proprietary chemical proteomics and quantitative mass spectrometry technologies to identify a small molecule's native cellular targets from biological samples.
PhosphoScout is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. PhosphoScout is applicable to both small molecules and antibodies.
"We are excited and pleased to partner with Daiichi Sankyo to support their endeavor in developing novel medicines for cancer patients," noted Andreas Jenne, Kinaxo's CEO, in a statement.
Kinaxo is a privately held biotechnology company based in Munich/Martinsried, Germany. It is a service company specializing in chemical proteomics and quantitative mass spectrometry methods to support the successful development of targeted drugs.
As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, Kinaxo continuously expands and improves its technology platform in collaboration with the leading Planck laboratories of Ullrich and Prof. Matthias Mann.
Kinaxo offers its clients extensive experience in chemical proteomics and phosphoproteomics applications and has several collaborations with global pharmaceutical companies such as Johnson & Johnson, Bayer, Roche and Boehringer Ingelheim.
Kinaxo in agreement with BMS
MARTINSRIED, Germany—Kinaxo Biotechnologies GmbH also recently announced that Bristol-Myers Squibb Co. (BMS) has chosen the company to support several of its drug discovery programs. Under the terms of the companies' agreement, Kinaxo will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at BMS to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.
"We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world," says Dr. Jutta Fritz, head of business development at KINAXO. "We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States."
Under terms of the agreement, Daiichi Sankyo will employ Kinaxo's technology platform to support the development of Daiichi Sankyo's targeted cancer drugs. This will involve Kinaxo applying its proprietary chemical proteomics technologies, Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology, PhosphoScout, within various research programs pursued at Daiichi Sankyo.
Financial details of the agreement were not disclosed.
In a statement, Daiichi Sankyo said this is the first time the two companies have worked together, and Kinaxo's prominent proteomics technologies made it an attractive partner for Daiichi Sankyo. Daiichi Sankyo added that Kinaxo's technologies can provide the potential of clinical applications for personalized medicine.
The goals of the collaboration are to target kinase validation and mode of action analysis.
"To promote innovation in cancer therapy, we need to better understand how targeted drugs interfere with de-regulated signaling in human malignancies," says Axel Ullrich, director at the Max Planck Institute for Biochemistry in Martinsried and a Kinaxo board member. "To this end, Kinaxo has established a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment. I am convinced that these innovative technologies will significantly contribute to the development of tomorrow's cancer therapeutics."
Cellular Target Profiling and KinAffinity use a combination of proprietary chemical proteomics and quantitative mass spectrometry technologies to identify a small molecule's native cellular targets from biological samples.
PhosphoScout is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. PhosphoScout is applicable to both small molecules and antibodies.
"We are excited and pleased to partner with Daiichi Sankyo to support their endeavor in developing novel medicines for cancer patients," noted Andreas Jenne, Kinaxo's CEO, in a statement.
Kinaxo is a privately held biotechnology company based in Munich/Martinsried, Germany. It is a service company specializing in chemical proteomics and quantitative mass spectrometry methods to support the successful development of targeted drugs.
As a spin-off of the Max Planck Institute of Biochemistry in Martinsried, Kinaxo continuously expands and improves its technology platform in collaboration with the leading Planck laboratories of Ullrich and Prof. Matthias Mann.
Kinaxo offers its clients extensive experience in chemical proteomics and phosphoproteomics applications and has several collaborations with global pharmaceutical companies such as Johnson & Johnson, Bayer, Roche and Boehringer Ingelheim.
Kinaxo in agreement with BMS
MARTINSRIED, Germany—Kinaxo Biotechnologies GmbH also recently announced that Bristol-Myers Squibb Co. (BMS) has chosen the company to support several of its drug discovery programs. Under the terms of the companies' agreement, Kinaxo will apply its chemical proteomics technologies to deconvolute molecular targets of compounds currently undergoing discovery research at BMS to enable more informed decisions at various stages of the drug discovery process, such as selecting the right compound for clinical development.
"We are very pleased to collaborate with Bristol-Myers Squibb, one of the most prestigious pharmaceutical companies in the world," says Dr. Jutta Fritz, head of business development at KINAXO. "We are looking forward to building a productive partnership with Bristol-Myers Squibb, and consider this move to be a major milestone in expanding our business in the United States."
